Colorectal Cancer
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 73 Shown
  • Learning Module cme-icon ce-icon

    Therapy Selection in Metastatic Colorectal Cancer

    In this CME/CE-certified activity, Tanios Bekaii-Saab, MD, FACP, reviews key data supporting evolving treatment choices for patients with metastatic colorectal cancer.
    Faculty: Tanios Bekaii-Saab MD, FACP
    Released: 11/21/2017
  • Downloadable Slides: Therapy Selection in Metastatic Colorectal Cancer

    In this downloadable slideset, Tanios Bekaii-Saab, MD, FACP, reviews current management strategies for patients with metastatic CRC along with key data supporting each approach.
    Date Posted: 11/21/2017
  • Expert Perspectives on Biosimilar Agents

    In these downloadable slides, a multidisciplinary panel of expert faculty discuss the use of biosimilars across oncology, rheumatology, dermatology, and gastroenterology specialties.
    Date Posted: 11/16/2017
  • Metastatic Colorectal Cancer: Areas of Consensus and Controversy Among Experts

    Tanios Bekaii-Saab MD, FACP - 10/31/2017 1 comment / Last Comment: 11/25/2017
    In this commentary on the treatment of metastatic colorectal cancer, I explore areas of consensus and controversy among experts including management of MSI-high/MMR-deficient tumors, treatment of transverse primaries, management of tumors with BRAF V600E mutations, and approaches in later lines of therapy.
  • Focus on Metastatic Colorectal Cancer: An Interactive Decision Support Tool

    This interactive treatment decision aid will let you compare your choice of therapy for patients with metastatic CRC with expert recommendations from Tanios Bekaii-Saab, MD, FACP; George A. Fisher, MD, PhD; Scott Kopetz, MD, PhD, FACP; John Strickler, MD; and Alan P. Venook, MD.
    Date Posted: 10/17/2017
  • How I Manage Patients With Chemotherapy-Refractory Metastatic CRC

    John Strickler MD - 9/11/2017 16 comments / Last Comment: 11/30/2017
    As patients progress through first-line and second-line therapy, selection of therapy becomes more complicated and nuanced. Here’s how I navigate the multiple treatment options.
  • Then and Now: My Take on Individualizing Therapy for Progressive Colorectal Cancer in 2017

    John L. Marshall MD - 8/21/2017 23 comments / Last Comment: 12/6/2017
    Later-line treatment options for CRC have expanded markedly since 2015. How should we use established and emerging molecular markers in 2017 to select the optimal regimen for each patient?
  • Combination Therapy With BRAF Inhibitors: A New Frontier in BRAF-Mutant CRC

    Scott Kopetz MD, PhD, FACP - 8/14/2017 6 comments / Last Comment: 11/26/2017
    BRAF-mutated CRC has a poor prognosis and limited treatment options. Read my thoughts on how combinations with BRAF inhibitors are offering promising benefits for this challenging population.
  • Learning Module cme-icon

    New Findings in Gastrointestinal Cancers

    In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.
    Faculty: Steven J. Cohen MD, Alan P. Venook MD
    Released: 8/7/2017
  • Testing for Microsatellite Instability in the Era of Immune Checkpoint Inhibitors

    John L. Marshall MD - 7/11/2017 3 comments / Last Comment: 8/8/2017
    Should we evaluate microsatellite status in all patients with colorectal cancer, regardless of stage and treatment experience? Read my thoughts on how I approach testing in my practice.
10 of 73 Shown
Show 10 More